Assure (IONM) Competitors

BIOLASE (NASDAQ:BIOL) and Assure (NASDAQ:IONM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Is BIOL or IONM more profitable?

BIOLASE has a net margin of -41.65% compared to Assure's net margin of -25,178.32%. Assure's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Assure	-25,178.32%	N/A	-249.78%

Does the media prefer BIOL or IONM?

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Assure'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Assure	Neutral

Which has more risk and volatility, BIOL or IONM?

BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Assure has a beta of 185.75, meaning that its stock price is 18,475% more volatile than the S&P 500.

Which has preferable earnings & valuation, BIOL or IONM?

BIOLASE has higher revenue and earnings than Assure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Assure	$149K	1.01	-$26.08M	N/A	N/A

Do analysts recommend BIOL or IONM?

BIOLASE presently has a consensus target price of $1.20, indicating a potential upside of 0.00%. Given BIOLASE's stronger consensus rating and higher possible upside, analysts plainly believe BIOLASE is more favorable than Assure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Assure	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals & insiders believe in BIOL or IONM?

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 3.3% of Assure shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by insiders. Comparatively, 3.8% of Assure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BIOLASE beats Assure on 8 of the 11 factors compared between the two stocks.